Risk assessment for the carotenoids lutein and lycopene
- PMID: 16814439
- DOI: 10.1016/j.yrtph.2006.05.007
Risk assessment for the carotenoids lutein and lycopene
Abstract
Lutein and lycopene, two prevalent carotenoids in the human diet have become increasingly popular ingredients in dietary supplements. A large body of human and animal research suggests that oral forms of these carotenoids may provide benefits in the areas of eye, prostate, skin and cardiovascular health. The increased awareness and use of these ingredients in dietary supplements warrants a comprehensive review of their safety. Systematic evaluation of the research designs and data provide a basis for risk assessment and the usual tolerable Upper Level of Intake (UL) derived from it if the newer methods described as the Observed Safe Level (OSL) or Highest Observed Intake (HOI) are utilized. The OSL risk assessment method indicates that the evidence of safety is strong at intakes up to 20mg/d for lutein, and 75 mg/d for lycopene, and these levels are identified as the respective OSL. Although much higher levels have been tested without adverse effects and may be safe, the data for intakes above these levels are not sufficient for a confident conclusion of long-term safety.
Comment in
-
Risk assessment of lutein and lycopene.Regul Toxicol Pharmacol. 2007 Apr;47(3):327-8; author reply 329. doi: 10.1016/j.yrtph.2006.10.005. Epub 2006 Nov 28. Regul Toxicol Pharmacol. 2007. PMID: 17134809 No abstract available.
Similar articles
-
Risk assessment for glucosamine and chondroitin sulfate.Regul Toxicol Pharmacol. 2007 Feb;47(1):78-83. doi: 10.1016/j.yrtph.2006.07.004. Epub 2006 Aug 30. Regul Toxicol Pharmacol. 2007. PMID: 16942821 Review.
-
Risk assessment for the amino acids taurine, L-glutamine and L-arginine.Regul Toxicol Pharmacol. 2008 Apr;50(3):376-99. doi: 10.1016/j.yrtph.2008.01.004. Epub 2008 Jan 26. Regul Toxicol Pharmacol. 2008. PMID: 18325648 Review.
-
Risk assessment for creatine monohydrate.Regul Toxicol Pharmacol. 2006 Aug;45(3):242-51. doi: 10.1016/j.yrtph.2006.05.005. Epub 2006 Jun 30. Regul Toxicol Pharmacol. 2006. PMID: 16814437 Review.
-
Risk assessment for coenzyme Q10 (Ubiquinone).Regul Toxicol Pharmacol. 2006 Aug;45(3):282-8. doi: 10.1016/j.yrtph.2006.05.006. Epub 2006 Jun 30. Regul Toxicol Pharmacol. 2006. PMID: 16814438 Review.
-
Risk assessment for carnitine.Regul Toxicol Pharmacol. 2006 Oct;46(1):23-8. doi: 10.1016/j.yrtph.2006.06.007. Epub 2006 Aug 9. Regul Toxicol Pharmacol. 2006. PMID: 16901595 Review.
Cited by
-
Potential Properties of Natural Nutraceuticals and Antioxidants in Age-Related Eye Disorders.Life (Basel). 2022 Dec 27;13(1):77. doi: 10.3390/life13010077. Life (Basel). 2022. PMID: 36676026 Free PMC article. Review.
-
Evaluation of antioxidant treatments for the modulation of macrophage function in the context of retinal degeneration.Mol Vis. 2019 Sep 5;25:479-488. eCollection 2019. Mol Vis. 2019. PMID: 31588172 Free PMC article.
-
Effects of lutein supplementation on inflammatory biomarkers and metabolic risk factors in adults with central obesity: study protocol for a randomised controlled study.Trials. 2020 Jan 6;21(1):32. doi: 10.1186/s13063-019-3998-8. Trials. 2020. PMID: 31907080 Free PMC article.
-
Lutein Supplementation for Eye Diseases.Nutrients. 2020 Jun 9;12(6):1721. doi: 10.3390/nu12061721. Nutrients. 2020. PMID: 32526861 Free PMC article. Review.
-
Potential Role of Natural Antioxidant Products in Oncological Diseases.Antioxidants (Basel). 2023 Mar 12;12(3):704. doi: 10.3390/antiox12030704. Antioxidants (Basel). 2023. PMID: 36978952 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical